Nadofaragene firadenovec

Therapeutic indications

Nadofaragene firadenovec is indicated for:

Non-muscle invasive bladder cancer with carcinoma in situ

Population group: only adults (18 years old or older)

Nadofaragene firadenovec is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Nadofaragene firadenovec is contraindicated in the following cases:

Prior hypersensitivity reactions to interferon alfa

at least one of
Interferon-A-2b allergy
Interferon-A-N1 allergy
Interferon-A-2a allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2023: ADSTILADRIN Suspension for intravesical instillation
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈